Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zykadia (Ceritinib) for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

Drug Name (Brand / Generic)

Zykadia / Ceritinib

Developed by

Novartis Pharmaceuticals

Product Description

Anaplastic lymphoma kinase (ALK) inhibitor

Current Indication

Non-small cell lung cancer (NSCLC)

Market Sector

Oncology

Development Status

Approved in the US and European Union (EU)
Expand

Go Top